Glass House, TerrAscend, Tilray, and Chicago Atlantic all made major announcements this week. Together, they tell a larger story about cannabis capital markets, M&A, and industry growth.

EBITDA may tell part of the story, but Free Cash Flow often tells the real story. Learn how sophisticated buyers value cannabis businesses.

Cannabis companies are beginning to reach major U.S. exchanges. Explore what cannabis stock uplisting could mean for investors, M&A, and industry growth.

Three major themes emerged from Cannabis Capital Conference 2026: returning capital, hemp beverages, and California’s strategic advantage.

Tilray’s $44 million BrewDog acquisition signals a major shift as a Canadian cannabis company expands into craft beer, positioning itself for future THC beverage markets.

Cannabis sales are hitting records in both the U.S. and Canada. With Schedule III reform advancing, growth is fueling investment and M&A.

Nature’s Miracle plans a $150 million greenhouse in California City. Here is how its scale compares to Glass House and what it means for the California flower market.

California reports $609M in illicit cannabis seized in 2025 and $1.2B since 2022. If enforcement holds, the regulated market may finally get a fair fight.

Schedule III is already influencing how cannabis companies think about expansion, research, and consolidation. Early strategic positioning by public operators may have lasting implications for cannabis M&A.

Reports suggest Trump may move cannabis to Schedule III by executive order. We examine the history, politics, and why reform still falls short.